MX355366B - Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion. - Google Patents

Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion.

Info

Publication number
MX355366B
MX355366B MX2015004592A MX2015004592A MX355366B MX 355366 B MX355366 B MX 355366B MX 2015004592 A MX2015004592 A MX 2015004592A MX 2015004592 A MX2015004592 A MX 2015004592A MX 355366 B MX355366 B MX 355366B
Authority
MX
Mexico
Prior art keywords
recombinant virus
replication deficient
cytotoxic
deficient recombinant
response against
Prior art date
Application number
MX2015004592A
Other languages
English (en)
Inventor
Brinkmann Kay
Baur Karen
Hausmann Jürgen
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of MX355366B publication Critical patent/MX355366B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un virus de la vaccinia modificado recombinante Ankara (MVA) que codifica para al menos un antígeno y/o epítopo antigéncico, caracterizado porque la expresión del antígeno y/o epítopo antigénico está regulada por un elemento de control transcripcional que comprende al menos dos elementos que conducen la expresión temprana del antígeno y/o epítopo antigénico, y el elemento de control transcripcional es un promotor temprano /tardío que comprende la secuencia de nucleótidos de SEQ ID NO: 1 o una secuencia de nucleótidos que tiene al menos 90% de identidad con la secuencia de nucleótidos de SEQ ID NO: 1, y en donde el MVA recombinante expresa en células HeLa un nivel del antígeno codificado en presencia de 40 µg/ml de AraC que es al menos 50% del nivel del antígeno codificado en ausencia de AraC.
MX2015004592A 2009-03-13 2010-03-11 Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion. MX355366B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15985709P 2009-03-13 2009-03-13
EP09009759 2009-07-28
PCT/EP2010/001545 WO2010102822A1 (en) 2009-03-13 2010-03-11 Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines

Publications (1)

Publication Number Publication Date
MX355366B true MX355366B (es) 2018-04-17

Family

ID=42115708

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015004592A MX355366B (es) 2009-03-13 2010-03-11 Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion.
MX2011008791A MX2011008791A (es) 2009-03-13 2010-03-11 Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2011008791A MX2011008791A (es) 2009-03-13 2010-03-11 Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion.

Country Status (16)

Country Link
US (1) US8394385B2 (es)
EP (2) EP2405939A1 (es)
JP (2) JP2012520061A (es)
KR (1) KR101752737B1 (es)
CN (1) CN102341120B (es)
AU (1) AU2010223524A1 (es)
BR (1) BRPI1009138B1 (es)
CA (1) CA2751301C (es)
EA (1) EA023832B1 (es)
IL (1) IL213572B (es)
MX (2) MX355366B (es)
MY (1) MY156997A (es)
NZ (1) NZ593525A (es)
SG (2) SG172115A1 (es)
WO (1) WO2010102822A1 (es)
ZA (1) ZA201106655B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8613936B2 (en) 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
AU2015203893A1 (en) * 2009-03-13 2015-08-06 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines
CA2813685A1 (en) 2010-10-15 2012-04-19 Josef Weigl Recombinant modified vaccinia virus ankara influenza vaccine
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
US10111946B2 (en) * 2012-06-22 2018-10-30 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
EP2912183B1 (en) * 2012-10-28 2020-05-06 Bavarian Nordic A/S Pr13.5 promoter for robust t-cell and antibody responses
WO2015142181A1 (en) 2014-03-21 2015-09-24 Furanix Technologies B.V. Polyesters comprising 2,5-furandicarboxylate and saturated diol units having a high glass transition temperature
KR20160140075A (ko) 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
ES2921605T3 (es) 2016-01-29 2022-08-30 Bavarian Nordic As Vacuna contra el virus de la encefalitis equina basada en el virus de la variolovacuna modificado Ankara (VMA) recombinante
MX2018013340A (es) * 2016-05-02 2019-08-21 Janssen Vaccines & Prevention Bv Combinaciones de vacunas terapeuticas para el vph.
KR102605505B1 (ko) 2016-09-28 2023-11-22 버베리안 노딕 에이/에스 폭스바이러스에서 이식유전자의 안정성을 강화시키는 조성물 및 방법
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
ES2905478T3 (es) 2016-12-28 2022-04-08 Transgene Sa Virus oncolíticos y moléculas terapéuticas
US11306179B2 (en) 2017-05-18 2022-04-19 Avantium Knowledge Centre B.V. Polyester copolymer
EP3625283B1 (en) 2017-05-18 2025-05-07 Avantium Knowledge Centre B.V. Polyester copolymer
US11229693B2 (en) 2017-06-15 2022-01-25 Janssen Vaccines & Prevention B.V. Poxvirus vectors encoding HIV antigens, and methods of use thereof
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
MX2020001856A (es) 2017-08-24 2020-07-13 Bavarian Nordic As Terapia de combinacion para tratar el cancer con administracion intravenosa de un virus vaccinia ankara modificado (mva) recombinante y un anticuerpo.
BR112020012273A2 (pt) 2017-12-19 2020-11-24 Janssen Sciences Ireland Unlimited Company métodos e composições para induzir uma resposta imune contra o vírus da hepatite b (hbv)
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
US20240269254A1 (en) 2018-10-05 2024-08-15 Bavarian Nordic A/S Combination Therapy for Treating Cancer with an Intravenous Administration of a Recombinant MVA and an Immune Checkpoint Antagonist or Agonist
US12390515B2 (en) 2018-11-20 2025-08-19 Bavarian Nordic A/S Therapy for treating cancer with an intratumoral or intravenous administration of a recombinant MVA encoding 4-1BBL (CD137L) and/or CD40L
KR20210094600A (ko) 2018-11-22 2021-07-29 아반티움 놀리지 센터 비.브이. 하나 이상의 폴리에스터 공중합체의 제조방법, 하나 이상의 올리고머, 올리고머 조성물 및 폴리에스터 공중합체의 제조방법
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
JP7644111B2 (ja) 2019-11-20 2025-03-11 バヴァリアン・ノルディック・アクティーゼルスカブ がんを治療するための腫瘍内及び／または静脈内投与用組み換えｍｖａウイルス
CA3181431A1 (en) * 2020-06-10 2021-12-16 Jurgen Hausmann A recombinant modified vaccinia virus ankara (mva) vaccine against coronavirus disease
WO2021260065A1 (en) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP3928789A1 (en) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022084333A1 (en) 2020-10-20 2022-04-28 Janssen Vaccines & Prevention B.V. Hiv vaccine regimens
WO2022269003A1 (en) 2021-06-23 2022-12-29 Consejo Superior De Investigaciones Cientificas MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN
EP4108257A1 (en) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein
EP4452305A1 (en) 2021-12-23 2024-10-30 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
US20250049903A1 (en) 2021-12-23 2025-02-13 Bavarian Nordic A/S Therapy for Modulating Immune Response with Recombinant MVA Encoding IL-12
WO2023135313A1 (en) * 2022-01-17 2023-07-20 Nouscom Ag Recombinant orthopox viral vector encoding immunostimulatory proteins for cancer treatment
US20250387463A1 (en) 2022-06-29 2025-12-25 Bavarian Nordic A/S Recombinant Modified saRNA (VRP) and Vaccinia Virus Ankara (MVA) Prime-Boost Regimen
JP2025528219A (ja) 2022-08-18 2025-08-26 トランジェーヌ キメラポックスウイルス
EP4648781A1 (en) 2023-01-12 2025-11-19 Bavarian Nordic A/S Recombinant modified sarna (vrp) for cancer vaccine
AU2024241503A1 (en) 2023-03-17 2025-08-14 Albert-Ludwigs-Universität Freiburg Hbv antigen formulation for treating hepatitis b
WO2025172435A1 (en) 2024-02-13 2025-08-21 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Hbv antigen formulation for treating hepatitis b
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
IL82104A0 (en) 1986-04-08 1987-10-30 Usa Recombinant vaccinia virus expressing human retrovirus genes and method for producing htlb-iii envelope proteins
US5747324A (en) 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
US5766598A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
CA2104649A1 (en) 1992-08-25 1994-02-26 Makoto Seki Antisense compounds complementary to hcv genome
DK1335987T4 (en) * 2000-11-23 2016-09-19 Bavarian Nordic As Modified variant of vaccinia virus Ankara
US7094412B2 (en) 2001-12-10 2006-08-22 Bavarian Nordic A/S Poxvirus containing formulations and process for preparing stable poxvirus containing compositions
DK1404852T3 (da) * 2002-05-16 2006-05-08 Bavarian Nordic As Ekspression af gener i modificeret vacciniavirus Ankara ved anvendelse af kokoppe-ATI-promotoren
PL375740A1 (en) * 2002-11-25 2005-12-12 Bavarian Nordic A/S Recombinant poxvirus comprising at least two cowpox ati promoters
ATE471383T1 (de) 2003-11-24 2010-07-15 Bavarian Nordic As Promotoren zur expression in modifiziertem vaccinia virus ankara
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines

Also Published As

Publication number Publication date
JP6130876B2 (ja) 2017-05-17
HK1161677A1 (zh) 2012-08-03
JP2012520061A (ja) 2012-09-06
CA2751301C (en) 2018-05-01
EA023832B1 (ru) 2016-07-29
WO2010102822A1 (en) 2010-09-16
EP3456349A1 (en) 2019-03-20
ZA201106655B (en) 2014-12-23
IL213572A0 (en) 2011-07-31
JP2015180216A (ja) 2015-10-15
KR20110129954A (ko) 2011-12-02
US20100233203A1 (en) 2010-09-16
CA2751301A1 (en) 2010-09-16
NZ593525A (en) 2012-12-21
US8394385B2 (en) 2013-03-12
EA201171128A1 (ru) 2012-08-30
BRPI1009138B1 (pt) 2022-04-05
IL213572B (en) 2018-05-31
CN102341120B (zh) 2016-05-18
SG172115A1 (en) 2011-07-28
MY156997A (en) 2016-04-15
MX2011008791A (es) 2011-09-29
AU2010223524A1 (en) 2011-07-07
KR101752737B1 (ko) 2017-06-30
EP2405939A1 (en) 2012-01-18
CN102341120A (zh) 2012-02-01
BRPI1009138A2 (pt) 2016-03-08
SG10201400593VA (en) 2014-06-27

Similar Documents

Publication Publication Date Title
MX2011008791A (es) Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion.
IL263249B (en) A polypeptide isolated from btv virus which causes an immune response in an animal and a polypeptide containing a DNA segment that codes for an epitope or an antigenic determinant of the btv polypeptide
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
PH12017500727A1 (en) Modified virus-like particles of cmv
BR112014020019A2 (pt) vetores poxvirais recombinantes expressando tanto proteínas da raiva e ox40 e vacinas feitos a partir destes
TR201903223T4 (tr) Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı.
MX351643B (es) Antigeno ndv recombinante y usos del mismo.
WO2010132561A3 (en) New human rotavirus strains and vaccines
MX2013004159A (es) Proteina vp6 de la capside de norovirus y de rotavirus para el uso como vacuna combinada.
EA201590829A1 (ru) Новые мукозные адъюванты и системы доставки
EA201290956A1 (ru) Вакцина против вич
WO2016130560A3 (en) Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats
PH12014501388A1 (en) A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
WO2010040847A3 (en) Recombinant protein bodies as immunogen-specific adjuvants
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
BR112014020025A2 (pt) vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
CL2012003219A1 (es) Parapoxvirus recombinante que comprende un parapoxvirus y adn heterólogo derivado de un virus de la rabia; procedimiento de preparación de dicho parapoxvirus; composicion inmunogénica; uso de la composicion para inducir respuesta inmunitaria contra el virus de la rabia en un animal.
WO2011100408A3 (en) Serologic correlates of protection against bacillis anthracis infection
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
WO2013173256A3 (en) New and improved influenza vaccines
BR112014023283A8 (pt) Composição imunogênica, segunda composição imunogênica, e, método para prevenção e/ou tratamento contra doença influenza
WO2010080188A3 (en) Epitope targeted anthrax vaccine
MX374919B (es) ANTÍGENOS Y COMBINACIONES DE ANTÍGENOS PARA USARSE PARA ELEVAR LA RESPUESTA INMUNE CONTRA Haemophilus influenzae.
AR078147A1 (es) Regimen de inmunizacion por sensibilizacion - refuerzo heterologa
WO2012178078A3 (en) Use of yscf, truncated yscf and yscf homologs as adjuvants